2 weeks Ago By Defense World Staff
Federated Hermes Inc. trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 23.
7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 736 shares of the medical equipment provider’s stock after selling 229 shares during the quarter. Federated Hermes Inc.
’s holdings in Zimmer Biomet were worth $78,000 as of its most recent SEC filing. A number of other large investors also recently added to or reduced their stakes in the business. Roman Butler Fullerton & Co.
bought a new stake in Zimmer Biomet in the 4th quarter valued at approximately $473,000. KLCM Advisors Inc. bought a new stake in shares of Zimmer Biomet in the fourth quarter worth $7,825,000.
Peddock Capital Advisors LLC acquired a new position in Zimmer Biomet during the fourth quarter worth $654,000. Van ECK Associates Corp grew its position in Zimmer Biomet by 5.9% in the fourth quarter.
Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Finally, Reinhart Partners LLC. increased its stake in Zimmer Biomet by 34.
4% in the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider’s stock valued at $9,164,000 after buying an additional 22,220 shares during the last quarter.
88.89% of the stock is currently owned by institutional investors and hedge funds. Zimmer Biomet Stock PerformanceNYSE ZBH opened at $97.
90 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.
91 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $105.
92 and a 200-day moving average price of $106.72. Zimmer Biomet Holdings, Inc.
has a twelve month low of $96.58 and a twelve month high of $123.96.
The firm has a market cap of $19.37 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 1.
95 and a beta of 0.84. Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its earnings results on Thursday, February 6th.
The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.
01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.
77%. During the same period in the previous year, the business posted $2.20 earnings per share.
As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.
Zimmer Biomet Dividend AnnouncementThe firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend.
This represents a $0.96 annualized dividend and a yield of 0.98%.
The ex-dividend date is Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.
Insider Transactions at Zimmer BiometIn related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.
20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20.
The trade was a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Company insiders own 0.95% of the company’s stock. Analyst Ratings ChangesSeveral research analysts recently commented on ZBH shares.
Royal Bank of Canada reduced their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th.
Truist Financial restated a “hold” rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th.
JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. BTIG Research restated a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th.
Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $124.
15.Check Out Our Latest Stock Analysis on ZBHZimmer Biomet Profile (Free Report)Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.
E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Featured ArticlesFive stocks we like better than Zimmer BiometHow to Profit From Value Investing J.B. Hunt Transport Overcorrects Into a Buying OpportunityManufacturing Stocks InvestingAppLovin: Can Record Profits Overcome Market Skepticism?Stock Market Sectors: What Are They and How Many Are There? MarketBeat Week in Review – 04/14 – 04/18Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report)..
